ArticleJACC. Case reports2026
Self-Expanding Supra-Annular Transcatheter Valve for Pure Native Aortic Insufficiency: Rationale and Technique.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective was to underscore the feasibility and safety of the Navitor self-expanding transcatheter aortic valve for off-label treatment of pure native aortic insufficiency (AI) in high surgical risk patients and provide a step-by-step procedural guide. KEY STEPS: Steps included: 1) analysis of computed tomography scans for ideal patient selection; 2) deployment of the Navitor transcatheter aortic valve; and 3) assessment of valve function using aortography and echocardiography. POTENTIAL PITFALLS: Device anchoring may be compromised by a lack of calcification, increasing the risk of migration, embolization, and malposition. Oversizing is crucial, but it also increases the risk of conduction disturbances and annular injuries. TAKE-HOME MESSAGES: The Navitor transcatheter aortic valve offers an innovative approach for high-surgical-risk pure native AI. While the procedural success depends on patient selection, careful sizing, and mitigation of anatomic and technical limitations, the Navitor transcatheter aortic valve can be a reasonable bridge therapy until dedicated transcatheter valves for severe AI are commercially approved and widely available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.